EST
WST icon

EA Series Trust’s West Pharmaceutical WST Stock Holding History

EA Series Trust’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$218K Buy
+569
New +$203K 0.01% 1055

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

EA Series Trust's WST Position: Q2 2023 in Review

EA Series Trust opened a new position in West Pharmaceutical (WST) in Q2 2023: 569 shares worth $218K. The stake represents 0.01% of the portfolio and ranks #1055 among its holdings.

734 funds tracked by Wall St. Rank hold WST as of Q2 2023.

  • EA Series Trust held 569 shares of West Pharmaceutical worth $218K as of Q2 2023.
  • West Pharmaceutical was a new EA Series Trust position in Q2 2023.
  • West Pharmaceutical made up 0.01% of EA Series Trust's portfolio in Q2 2023, its #1055 holding.
  • 734 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2023.

Based on EA Series Trust's 13F filing for Q2 2023, filed 27 Jul 2023.